RecruitingNot ApplicableNCT07435662

Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver


Sponsor

Denver Health and Hospital Authority

Enrollment

40 participants

Start Date

Oct 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Numerous pharmacotherapies have been proven to reduce mortality and hospitalization rates for heart failure with reduced ejection fraction (HFrEF) patients. However, these are underutilized clinically, preventing realization of proven benefits. Simplified patient education tools and multidisciplinary teams including pharmacists have been used to improve medication optimization but in predominantly private payer groups. This study will translate these evidence-based interventions to patients with limited access to care. In this randomized, prospective study, patients with HFrEF at a local hospital dedicated to care for participants with limited access will receive either pharmacist-directed medication adjustment visits with patient education materials or standard of care. This study will assess the hypothesis that the implementation of the intervention is feasible in this population, as demonstrated by the number of visits and proportion of visits with medication adjustments. Further, medication dosing in each arm will be evaluated via the Kansas City Medication Optimization (KCMO) score, which will average the percentage of maximal doses of appropriate HFrEF medication classes a patient is on. The change in KCMO scores over the course of the pilot in the two arms will then be compared to assess the hypothesis that the intervention will better increase patients' KCMO scores than the standard of care. The findings of this study will help address knowledge gaps in the care of patients not well represented previously in the literature. This proposal addresses the translational science roadblock of recruitment and engagement of participants with limited access to care.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study works to improve heart failure treatment for underserved patients at Denver Health — focusing on people with reduced heart pumping function who may not be receiving the full range of recommended medications. **You may be eligible if...** - You are 18 or older - You have heart failure with reduced ejection fraction (your heart is pumping at 40% or less of normal) - You receive your care within the Denver Health and Hospital Authority (DHHA) system **You may NOT be eligible if...** - Your kidney function is very low (eGFR below 25) or you are on dialysis - You have cirrhosis (severe liver scarring) - You are unable to provide consent - You do not speak English or Spanish Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPharmacy follow up

Patients in the intervention will have additional follow ups with pharmacy between heart failure provider visits. They will also receive specialized simple patient education re: heart failure meds.


Locations(1)

Denver Health and Hospital Authority

Denver, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07435662


Related Trials